Cytokine induced RelB/p50 complexes drive mesenchymal glioma progression

细胞因子诱导的 RelB/p50 复合物驱动间充质胶质瘤进展

基本信息

  • 批准号:
    9050158
  • 负责人:
  • 金额:
    $ 3.51万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-03-25 至 2021-03-24
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant) In the past 25 years, little improvement has been made in patient survival after a diagnosis of glioblastoma multiforme (GBM). The robust induction of angiogenesis, extreme resistance to radiation, and a highly aggressive, invasive phenotype make GBM one of the most lethal and difficult human cancers to treat. Recently, a mesenchymal subtype of GBMs has been identified that displays the most infiltrative behavior, is the most resistant to standard therapies, and expresses markers, such as a secreted protein YKL-40, which correlate with the worst patient prognosis. We have identified that two proinflammatory cytokines, interleukin-1β (IL-1β) and oncostatin M (OSM), are specifically overexpressed in patients with mesenchymal GBM. Our data indicates that IL-1β and OSM synergize to support GBM progression through a novel RelB/p50-canonical pathway, which to date has only been proposed to function in cells expressing high levels of RelB. Our preliminary studies have identified two groups of RelB/p50-dependent genes in GBM cells and astrocytes: "conserved" genes (activated in both GBM and astrocytes) and "aberrantly-activated" genes (activated in GBM but suppressed in astrocytes). The "conserved" genes include markers of the mesenchymal GBM subtype and intriguing novel genes postulated to regulate GBM progression. The "aberrantly activated" genes encode many cytokines, including IL-1, which suggests the existence of RelB-driven feedforward cytokine loop fueling chronic inflammation in GBM. Importantly, the "aberrantly-activated" genes have previously been shown to undergo RelB-dependent reprograming by epigenetic silencing in macrophages, which requires histone deacetylase SIRT1. Our preliminary studies have found that one allele of the sirt1 gene is deleted in 75% of GBM tumors, which may explain the lack of RelB-dependent epigenetic silencing in GBM. Thus, we hypothesize that RelB/p50 activation drives gene expression programs which induced both chronic inflammation and GBM aggressiveness.
 描述(由申请人提供) 在过去的25年里,在被诊断为多形性胶质母细胞瘤(GBM)后,患者的存活率几乎没有改善。强大的血管生成诱导,对辐射的极端抵抗力,以及高度侵袭性和侵袭性的表型使GBM成为最致命和最难治疗的人类癌症之一。最近,已发现一种间充质细胞亚型,它表现出最具浸润性的行为,对标准治疗最具抵抗力,并表达与最差患者预后相关的标志物,如分泌蛋白YKL-40。我们已经发现两种促炎细胞因子,白介素1β(IL-1β)和抑癌素M(Osm)在间叶性基底膜患者中特异性地过度表达。我们的数据表明,IL-1β和OSM通过一种新的RelB/p50-规范途径协同支持基底膜的进展,到目前为止,这一途径仅被认为在表达高水平RelB的细胞中起作用。我们的初步研究已经在GBM细胞和星形胶质细胞中发现了两组依赖RelB/p50的基因:“保守”基因(在GBM和星形胶质细胞中都激活)和“异常激活”基因(在GBM中激活,但在星形胶质细胞中抑制)。这些“保守的”基因包括间充质基底膜亚型的标记,以及被认为调节基底膜进展的有趣的新基因。这些“异常激活”的基因编码许多细胞因子,包括IL-1,这表明存在由RelB驱动的前馈细胞因子环,助长了GBM的慢性炎症。重要的是,“异常激活”的基因此前已被证明在巨噬细胞中通过表观遗传沉默而经历了依赖于RelB的重新编程,这需要组蛋白脱乙酰基酶SIRT1。我们的初步研究发现,在75%的GBM肿瘤中,SIRT1基因的一个等位基因缺失,这可能解释了GBM中缺乏RelB依赖的表观遗传沉默。因此,我们假设RelB/p50激活驱动基因表达程序,从而诱导慢性炎症和GBM侵袭性。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Michael Waters其他文献

Michael Waters的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似海外基金

Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
  • 批准号:
    502556
  • 财政年份:
    2024
  • 资助金额:
    $ 3.51万
  • 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
  • 批准号:
    10659303
  • 财政年份:
    2023
  • 资助金额:
    $ 3.51万
  • 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
  • 批准号:
    10674405
  • 财政年份:
    2023
  • 资助金额:
    $ 3.51万
  • 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
  • 批准号:
    10758772
  • 财政年份:
    2023
  • 资助金额:
    $ 3.51万
  • 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
  • 批准号:
    10676499
  • 财政年份:
    2023
  • 资助金额:
    $ 3.51万
  • 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
  • 批准号:
    2748611
  • 财政年份:
    2022
  • 资助金额:
    $ 3.51万
  • 项目类别:
    Studentship
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
  • 批准号:
    10532032
  • 财政年份:
    2022
  • 资助金额:
    $ 3.51万
  • 项目类别:
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
  • 批准号:
    22K05630
  • 财政年份:
    2022
  • 资助金额:
    $ 3.51万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
  • 批准号:
    10525070
  • 财政年份:
    2022
  • 资助金额:
    $ 3.51万
  • 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
  • 批准号:
    10689017
  • 财政年份:
    2022
  • 资助金额:
    $ 3.51万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了